Myasthenia Gravis  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
REGAIN, NCT01997229 / 2013-003589-15: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis ( Study)

Checkmark ICNMD 2016: REGAIN
Jul 2016 - Jul 2016: ICNMD 2016: REGAIN
Checkmark REGAIN
Jun 2016 - Jun 2016: REGAIN
Completed
3
125
Europe, Canada, Japan, US, RoW
Eculizumab, Placebo
Alexion Pharmaceuticals
Refractory Generalized Myasthenia Gravis
02/16
06/16
NCT02301624 / 2013-002191-41: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Completed
3
117
Europe, Canada, Japan, US, RoW
Eculizumab, Placebo
Alexion Pharmaceuticals
Refractory Generalized Myasthenia Gravis
01/19
01/19
NCT03759366 / 2016-001384-37: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Completed
3
11
Europe, Japan, US
Eculizumab
Alexion Pharmaceuticals, Inc.
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
01/22
11/23

Download Options